Opin vísindi

Fletta eftir höfundi "Rodríguez-Antona, Cristina"

Fletta eftir höfundi "Rodríguez-Antona, Cristina"

Röðun: Raða: Niðurstöður:

  • Svedberg, Anna; Björn, Niclas; Sigurgeirsson, Benjamín; Pradhananga, Sailendra; Brandén, Eva; Koyi, Hirsh; Lewensohn, Rolf; De Petris, Luigi; Apellániz-Ruiz, María; Rodríguez-Antona, Cristina; Lundeberg, Joakim; Gréen, Henrik (Elsevier BV, 2020-09)
    Objectives: Gemcitabine/carboplatin treatment is known to cause severe adverse drug reactions which can lead to the need for reduction or cessation of chemotherapy. It would be beneficial to identify patients at risk of severe hematological toxicity ...
  • Liu, Xiaoyan; Swen, Jesse J.; Diekstra, Meta H.M.; Boven, Epie; Castellano, Daniel; Gelderblom, Hans; Mathijssen, Ron H.J.; Vermeulen, Sita H.; Oosterwijk, Egbert; Junker, Kerstin; Roessler, Max; Alexiusdottir, Kristin; Sverrisdóttir, Ásgerður; Radu, Marius T.; Ambert, Valentin; Eisen, Tim; Warren, Anne; Rodríguez-Antona, Cristina; García-Donas, Jesus; Böhringer, Stefan; Koudijs, Karel K.M.; Kiemeney, Lambertus A.L.M.; Rini, Brian I.; Guchelaar, Henk-Jan (2018-05-15)
    Purpose: The survival of patients with clear cell metastatic renal cell carcinoma (cc-mRCC) has improved substantially since the introduction of tyrosine kinase inhibitors (TKI). With the fact that TKIs interact with immune responses, we investigated ...